METHYLPHENIDATE HYDROCHLORIDE tablet

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv ingrediens:

METHYLPHENIDATE HYDROCHLORIDE (UNII: 4B3SC438HI) (METHYLPHENIDATE - UNII:207ZZ9QZ49)

Tilgjengelig fra:

KVK-TECH, INC.

INN (International Name):

METHYLPHENIDATE HYDROCHLORIDE

Sammensetning:

METHYLPHENIDATE HYDROCHLORIDE 5 mg

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

Methylphenidate hydrochloride tablets are indicated for the treatment of: - Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults - Narcolepsy - Hypersensitivity to methylphenidate or other components of Methylphenidate hydrochloride tablets. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate [see Adverse Reactions (6.1)] . - Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions (7.1)] . Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including Methylphenidate hydrochloride tablets, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting https://womensmentalhealth.org/adhd-medications/. Risk Summary Published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There may be risks to the fetus associated with the use of CNS stimulants use during pregnancy (see Clinical Considerations) . No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 10 and 15 times, respectively, the maximum recommended human dose (MRHD) of 60 mg/day given to adolescents on a mg/m2 basis. However, spina bifida was observed in rabbits at a dose 52 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre- and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 6 times the MRHD given to adolescents (see Data) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions CNS stimulants, such as Methylphenidate hydrochloride tablets, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers. Data Animal Data In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Malformations (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 52 times the MRHD of 60 mg/day given to adolescents on a mg/m2 basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (15times the MRHD given to adolescents on a mg/m2 basis). There was no evidence of morphological development effects in rats, although increased incidences of fetal skeletal variations were seen at the highest dose level (10 times the MRHD of 60 mg/day given to adolescents on a mg/m2 basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (3 times the MRHD on a mg/m2 basis). When methylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 45 mg/kg/day, offspring body weight gain was decreased at the highest dose (6 times the MRHD of 60 mg/day given to adolescents on a mg/m2 basis), but no other effects on postnatal development were observed. The no effect level for pre- and postnatal development in rats was 15 mg/kg/day (approximately 2 times the MRHD given to adolescents on a mg/m2 basis). Risk Summary Limited published literature, based on milk sampling from seven mothers reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Methylphenidate hydrochloride tablets and any potential adverse effects on the breastfed infant from Methylphenidate hydrochloride tablets or from the underlying maternal condition. Clinical Considerations Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. The safety and effectiveness of Methylphenidate hydrochloride tablets for the treatment of ADHD have been established in pediatric patients 6 to 17 years. The safety and effectiveness of Methylphenidate hydrochloride tablets in pediatric patients less than 6 years have not been established. The long-term efficacy of Methylphenidate hydrochloride tablets in pediatric patients has not been established. Long-Term Suppression of Growth Growth should be monitored during treatment with stimulants, including Methylphenidate hydrochloride tablets. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.7)] . Juvenile Animal Toxicity Data Rats treated with methylphenidate early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood. A deficit in acquisition of a specific learning task was observed in females only. The doses at which these findings were observed are at least 4 times the MRHD of 60 mg/day given to children on a mg/m2 basis. In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal Week 10). When these animals were tested as adults (postnatal Weeks 13 to 14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 4 times the MRHD of 60 mg/day given to children on a mg/m2 basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (8 times the MRHD given to children on a mg/m2 basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (approximately 0.5 times the MRHD given to children on a mg/m2 basis). The clinical significance of the long-term behavioral effects observed in rats is unknown. Methylphenidate hydrochloride tablets has not been studied in the geriatric population. Methylphenidate hydrochloride tablets contain methylphenidate hydrochloride, a Schedule II controlled substance.  Methylphenidate hydrochloride tablets has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. Methylphenidate hydrochloride tablets can be diverted for non-medical use into illicit channels or distribution. Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Misuse and abuse of methylphenidate hydrochloride may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including Methylphenidate hydrochloride tablets, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Physical Dependence Methylphenidate hydrochloride tablets may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including Methylphenidate hydrochloride tablets include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation. Tolerance Methylphenidate hydrochloride tablets may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Produkt oppsummering:

Methylphenidate hydrochloride tablets, USP are available as follows: Tablets 5 mg- Yellow, round, flat faced beveled edge tablets, debossed “K” above “100” on one side and plain on other side. Bottles of 100 NDC 10702-100-01 Tablets 10 mg- Pale green colored, round, biconvex tablets debossed “K” above bisect “101” on one side and plain on the other side. Bottles of 100 NDC 10702-101-01 Tablets 20 mg- Light yellow, round, biconvex tablets debossed “K” above bisect “102” on one side and plain on the other side. Bottles of 100 NDC 10702-102-01 Store at 20°C to 25°C (68°F to 77°F), excursions permitted 15°C and 30°C (59°F and 86°F). [see USP controlled room temperature]. Protect from light. Dispense in tight, light-resistant container (USP).

Autorisasjon status:

Abbreviated New Drug Application

Informasjon til brukeren

KVK-TECH, INC.
----------
MEDICATION GUIDE
Methylphenidate Hydrochloride Tablets CII
(meth’’ il fen’ i date hye” droe klor’ ide)
What is the most important information I should know about
Methylphenidate hydrochloride tablets?
Methylphenidate hydrochloride tablets may cause serious side effects,
including:
• Abuse, misuse, and addiction. Methylphenidate hydrochloride
tablets has a high chance for abuse and
misuse and may lead to substance use problems, including addiction.
Misuse and abuse of Methylphenidate
hydrochloride tablets, other methylphenidate containing medicines, and
amphetamine containing medicines,
can lead to overdose and death. The risk of overdose and death is
increased with higher doses of
Methylphenidate hydrochloride tablets or when it is used in ways that
are not approved, such as snorting or
injection.
o Your healthcare provider should check you or your child’s risk for
abuse, misuse, and addiction before
starting treatment with Methylphenidate hydrochloride tablets and will
monitor you or your child during
treatment.
o Methylphenidate hydrochloride tablets may lead to physical
dependence after prolonged use, even if taken
as directed by your healthcare provider.
o Do not give Methylphenidate hydrochloride tablets to anyone else.
See “ What is Methylphenidate
hydrochloride tablets?” for more information.
o Keep Methylphenidate hydrochloride tablets in a safe place and
properly dispose of any unused medicine.
See “ How should I store Methylphenidate hydrochloride tablets?”
for more information.
o Tell your healthcare provider if you or your child have ever abused
or been dependent on alcohol,
prescription medicines, or street drugs.
• Risks for people with serious heart disease. Sudden death has
happened in people who have heart defects
or other serious heart disease.
Your healthcare provider should check you or your child carefully for
heart problems before starting
Methylphenidate hydrochloride tablets.
Tell your healthcare provider if you or your child have any heart

Preparatomtale

METHYLPHENIDATE HYDROCHLORIDE- METHYLPHENIDATE HYDROCHLORIDE TABLET
KVK-TECH, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
METHYLPHENIDATE
HYDROCHLORIDE TABLETS USP CII SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR
METHYLPHENIDATE HYDROCHLORIDE TABLETS USP CII.
METHYLPHENIDATE HYDROCHLORIDE TABLETS, FOR ORAL USE, CII
INITIAL U.S. APPROVAL: 1955
WARNING: ABUSE, MISUSE, AND ADDICTION
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
Methylphenidate hydrochloride tablets has a high potential for abuse
and misuse, which can lead to
the development of a substance use disorder, including addiction.
Misuse and abuse of CNS
stimulants, including Methylphenidate hydrochloride tablets, can
result in overdose and death (5.1,
9.2, 10):
• Before prescribing Methylphenidate hydrochloride tablets, assess
each patient’s risk for abuse,
misuse,and addiction.
• Educate patients and their families about these risks, proper
storage of the drug, and proper
disposal of any unused drug.
• Throughout treatment, reassess each patient’s risk and
frequently monitor for signs and symptoms
of abuse, misuse, and addiction.
RECENT MAJOR CHANGES
Boxed Warning 10/2023
Dosage and Administration (2.1) 10/2023
Warnings and Precautions (5.1, 5.2, 5.8, 5.9, 5.10) 10/2023
INDICATIONS AND USAGE
Methylphenidate hydrochloride tablets is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit Hyperactivity Disorders (ADHD) and
Narcolepsy (1). (1)
DOSAGE AND ADMINISTRATION
(2)
Pediatric Patients 6 Years and Older: Start with 5 mg twice daily
(before breakfast and lunch), titrating
the dose weekly in 5- to 10-mg increments. Dosages above 60 mg/day are
not recommended (2.2).
Adults: Average daily dosage is 20 mg to 30 mg, administered 2 or 3
times daily, preferably 30 to 45
minutes before meals. Maximum total daily dosage is 60 mg (2.2).
DOSAGE FORMS AND STRENGTHS
Tablets: 5 mg, 10 mg, and 20 mg (3)
CONTRAINDICATI